发明名称 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
摘要 The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:;;where A, B, W1, W2, W3, and R1-R6 are described herein.
申请公布号 US2016083365(A1) 申请公布日期 2016.03.24
申请号 US201514858165 申请日期 2015.09.18
申请人 Forma Therapeutics, Inc. 发明人 Lin Jian;Ericsson Anna;Campbell Ann-Marie;Gustafson Gary;Wang Zhongguo;Diebold R Bruce;Ashwell Susan;Lancia, JR. David R.;Caravella Justin Andrew;Lu Wei
分类号 C07D401/12;C07D401/14;C07D403/12;C07D413/14;C07D471/04;C07D409/14;C07D405/14;C07D417/14 主分类号 C07D401/12
代理机构 代理人
主权项 1. A compound of Formula (I): or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, prodrug, isomer, and tautomer thereof, wherein: each W1 and W2 are independently CH, CF, or N; W3 is independently, CR2, or N; A is selected from the group consisting of H, D, halogen, CN, —CHO, —COOH, —COOR, —C(O)NH2, —C(O)NHR, —S(O)Me, —S(O)2Me, B is selected from the group consisting of: H, D, OH, NH2, —NR7R8, CN, C1-C6 alkyl, C3-C8 cycloalkyl, substituted aryl, C1-C6 alkoxy, substituted heteroaryl, —(CH2)nC(O)NHR, —C(O)NH2, —(CH2)nNHR′C(O)R, —SR, —(CHR′)nS(O)R, —(CHR′)nS(O)2R, —COOR,wherein X and Y are independently in each occurrence C, N, NR, S, and O, provided that the ring containing X and Y cannot have more than 4 N or NR atoms or more than one S or O atoms; R and R′ at each occurrence are independently selected from the group consisting of H, halogen, —C(O)C1-C3 alkyl, —C(O)OC1-C3 alkyl, -, CF3, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkylalkyl, C3-C8 heterocyclyl, aryl, and heteroaryl, wherein each R or R′ is optionally further substituted with one or more substituents independently selected from the group consisting of OH, halogen, C1-C6 alkoxy, NH2, CN, C3-C8 cycloalkyl, C3-C8 heterocyclyl, aryl, and heteroaryl; R1 is independently H, OH, CN, halogen, CF3, CHF2, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C3-C8 heterocyclyl, aryl, or heteroaryl, wherein each C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C3-C8 heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, OH, NH2, CN, C1-C6 alkyl, and C1-C6 alkoxy; R2 is independently H, OH, CN, halogen, CF3, CHF2, benzyl, C1-C6 alkyl, C1-C6 alkoxy, NH2, NHR7, —N(R7)(R8), NHC(O)R7, NHS(O)R7, NHS(O)2R7, NHC(O)OR7, NHC(O)NHR7, —S(O)2NHR7, NHC(O)N(R8)R7, OCH2R7, OCHRR′, CHRR′, or OCHR′R7, wherein C1-C6 alkyl and C1-C6 alkoxy are optionally substituted with one or more substituents independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C3-C8 heterocyclyl, aryl, and heteroaryl; R3 is H or C1-C6 alkyl; R4 and R5 are independently H, C1-C3 alkyl, CH2OH, or C1-C3 alkyl substituted with one or more halogen, or R4 and R5 when combined can form a C3-C6 cycloalkyl or C3-C6 heterocyclyl; R6 is H, halogen, CF3, CHF2, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, or C3-C8 cycloalkyl; R7 and R8 are independently H, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C3-C8 heterocyclyl, aryl, or heteroaryl; or when combined R7 and R8 can form a C3-C8 heterocyclyl or heteroaryl ring; n is 0, 1, or 2; and r is 0, 1, or 2; with the proviso that when R1 is H and R2 is F, then B is
地址 Watertown MA US